• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

非酒精性脂肪性肝病：病理学家的视角。

Non-alcoholic fatty liver disease: the pathologist's perspective.

机构信息

Department of Anatomical Pathology, Singapore General Hospital, Singapore, Singapore.

Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

出版信息

Clin Mol Hepatol. 2023 Feb;29(Suppl):S302-S318. doi: 10.3350/cmh.2022.0329. Epub 2022 Nov 15.

DOI:10.3350/cmh.2022.0329
PMID:36384146
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10029955/
Abstract

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of diseases characterized by fatty accumulation in hepatocytes, ranging from steatosis, non-alcoholic steatohepatitis, to cirrhosis. While histopathological evaluation of liver biopsies plays a central role in the diagnosis of NAFLD, limitations such as the problem of interobserver variability still exist and active research is underway to improve the diagnostic utility of liver biopsies. In this article, we provide a comprehensive overview of the histopathological features of NAFLD, the current grading and staging systems, and discuss the present and future roles of liver biopsies in the diagnosis and prognostication of NAFLD.

摘要

非酒精性脂肪性肝病（NAFLD）是一种以肝细胞脂肪堆积为特征的疾病谱，范围从单纯性脂肪变性、非酒精性脂肪性肝炎到肝硬化。虽然肝活检的组织病理学评估在 NAFLD 的诊断中起着核心作用，但仍存在观察者间变异性等问题，目前正在积极研究以提高肝活检的诊断效用。本文全面概述了 NAFLD 的组织病理学特征、目前的分级和分期系统，并讨论了肝活检在 NAFLD 的诊断和预后中的当前和未来作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd81/10029955/2701960fd0e7/cmh-2022-0329f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd81/10029955/efc2eb23b240/cmh-2022-0329f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd81/10029955/fdb04db083fc/cmh-2022-0329f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd81/10029955/41da37b37caa/cmh-2022-0329f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd81/10029955/95fcf2093de5/cmh-2022-0329f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd81/10029955/2701960fd0e7/cmh-2022-0329f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd81/10029955/efc2eb23b240/cmh-2022-0329f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd81/10029955/fdb04db083fc/cmh-2022-0329f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd81/10029955/41da37b37caa/cmh-2022-0329f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd81/10029955/95fcf2093de5/cmh-2022-0329f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd81/10029955/2701960fd0e7/cmh-2022-0329f5.jpg

相似文献

1
Non-alcoholic fatty liver disease: the pathologist's perspective.非酒精性脂肪性肝病：病理学家的视角。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S302-S318. doi: 10.3350/cmh.2022.0329. Epub 2022 Nov 15.
2
Deep learning-based quantification of NAFLD/NASH progression in human liver biopsies.基于深度学习的人类肝活检中 NAFLD/NASH 进展的定量评估。
Sci Rep. 2022 Nov 10;12(1):19236. doi: 10.1038/s41598-022-23905-3.
3
High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease.高通量、基于机器学习的非酒精性脂肪性肝病患者肝活检组织中脂肪变性、炎症、气球样变、纤维化的定量分析。
Clin Gastroenterol Hepatol. 2020 Aug;18(9):2081-2090.e9. doi: 10.1016/j.cgh.2019.12.025. Epub 2019 Dec 27.
4
Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children.成人及儿童非酒精性脂肪性肝病和非酒精性脂肪性肝炎的组织学
Clin Liver Dis. 2016 May;20(2):293-312. doi: 10.1016/j.cld.2015.10.011. Epub 2015 Dec 28.
5
Non-invasive diagnosis and staging of non-alcoholic fatty liver disease.非酒精性脂肪性肝病的无创诊断和分期。
Hormones (Athens). 2022 Sep;21(3):349-368. doi: 10.1007/s42000-022-00377-8. Epub 2022 Jun 4.
6
Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.非酒精性脂肪性肝病——组织学评分系统：一项大型队列单中心评估研究。
APMIS. 2017 Nov;125(11):962-973. doi: 10.1111/apm.12742.
7
Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease.评估非酒精性脂肪性肝病进展的活检和非侵入性方法。
Gastroenterology. 2016 Jun;150(8):1811-1822.e4. doi: 10.1053/j.gastro.2016.03.008. Epub 2016 Mar 19.
8
Pathology of non-alcoholic fatty liver disease.非酒精性脂肪性肝病的病理学。
Liver Int. 2017 Jan;37 Suppl 1:85-89. doi: 10.1111/liv.13301.
9
Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease.1-脱氧鞘氨醇与非酒精性脂肪性肝病中的脂肪变性相关，但与脂肪性肝炎和肝纤维化无关。
Acta Diabetol. 2021 Mar;58(3):319-327. doi: 10.1007/s00592-020-01612-7. Epub 2020 Oct 21.
10
Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH).非酒精性脂肪性肝炎（NASH）的组织病理学诊断。
Methods Mol Biol. 2022;2455:1-18. doi: 10.1007/978-1-0716-2128-8_1.

引用本文的文献

1
Assessing Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Patients at a Tertiary Hospital, Addis Ababa, Ethiopia.埃塞俄比亚亚的斯亚贝巴一家三级医院对2型糖尿病患者的非酒精性脂肪性肝病评估。
J Diabetes Res. 2025 Aug 23;2025:5555842. doi: 10.1155/jdr/5555842. eCollection 2025.
2
Mechanism of Huanglian Wendan Decoction in ameliorating non-alcoholic fatty liver disease via modulating gut microbiota-mediated metabolic reprogramming and activating the LKB1/AMPK pathway.黄连温胆汤通过调节肠道微生物群介导的代谢重编程和激活LKB1/AMPK途径改善非酒精性脂肪性肝病的机制
PLoS One. 2025 Sep 2;20(9):e0331303. doi: 10.1371/journal.pone.0331303. eCollection 2025.
3

本文引用的文献

1
Histopathological Variants of Hepatocellular Carcinomas: an Update According to the 5th Edition of the WHO Classification of Digestive System Tumors.肝细胞癌的组织病理学变异：根据世界卫生组织消化系统肿瘤分类第5版的更新
J Liver Cancer. 2020 Mar;20(1):17-24. doi: 10.17998/jlc.20.1.17. Epub 2020 Mar 31.
2
Reliability of the nonalcoholic steatohepatitis clinical research network and steatosis activity fibrosis histological scoring systems.非酒精性脂肪性肝炎临床研究网络及脂肪变性活动度纤维化组织学评分系统的可靠性
J Gastroenterol Hepatol. 2022 Jun;37(6):1131-1138. doi: 10.1111/jgh.15843. Epub 2022 Apr 6.
3
Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score.
Deep learning-based method for grading histopathological liver fibrosis in rodent models of metabolic dysfunction-associated steatohepatitis.
基于深度学习的代谢功能障碍相关脂肪性肝炎啮齿动物模型肝组织病理学纤维化分级方法
Front Med (Lausanne). 2025 Jul 4;12:1629036. doi: 10.3389/fmed.2025.1629036. eCollection 2025.
4
Efficacy of interventions with live combined and enteric-coated capsules in metabolic associated fatty liver disease patients: a meta-analysis of randomized controlled trials.活组合及肠溶胶囊干预对代谢相关脂肪性肝病患者的疗效：一项随机对照试验的荟萃分析
Front Pharmacol. 2025 May 27;16:1610426. doi: 10.3389/fphar.2025.1610426. eCollection 2025.
5
Pharmacological Activation of AMP-activated Protein Kinase Ameliorates Liver Fibrosis in a Metabolic Dysfunction-Associated Steatohepatitis Mouse Model.在代谢功能障碍相关脂肪性肝炎小鼠模型中，AMP激活的蛋白激酶的药理学激活可改善肝纤维化。
Int J Biol Sci. 2025 Apr 21;21(7):2957-2972. doi: 10.7150/ijbs.108731. eCollection 2025.
6
Therapeutic potential of L. extract and atorvastatin in HFD-induced MAFLD: in vitro and in vivo exploration.L提取物和阿托伐他汀在高脂饮食诱导的MAFLD中的治疗潜力：体内外研究
3 Biotech. 2025 Jun;15(6):155. doi: 10.1007/s13205-025-04322-5. Epub 2025 May 6.
7
Multiple machine learning algorithms identify 13 types of cell death-critical genes in large and multiple non-alcoholic steatohepatitis cohorts.多种机器学习算法在大型多组非酒精性脂肪性肝炎队列中识别出13种细胞死亡关键基因。
Lipids Health Dis. 2025 May 8;24(1):169. doi: 10.1186/s12944-025-02588-5.
8
Investigating the Effects of Gossypetin on Liver Health in Diet-Induced Pre-Diabetic Male Sprague Dawley Rats.研究棉皮素对饮食诱导的糖尿病前期雄性斯普拉格-道利大鼠肝脏健康的影响。
Molecules. 2025 Apr 19;30(8):1834. doi: 10.3390/molecules30081834.
9
Elevated red blood cell folate levels are associated with metabolic dysfunction-associated steatotic liver disease: results from NHANES 2017-2020.红细胞叶酸水平升高与代谢功能障碍相关脂肪性肝病有关：2017 - 2020年美国国家健康与营养检查调查结果
Front Physiol. 2025 Mar 20;16:1494863. doi: 10.3389/fphys.2025.1494863. eCollection 2025.
10
Unraveling the molecular mechanisms of Fufangduzhong formula in alleviating high-fat diet-induced non-alcoholic fatty liver disease in mice.解析复方杜仲方缓解高脂饮食诱导的小鼠非酒精性脂肪性肝病的分子机制。
Front Pharmacol. 2025 Mar 12;16:1542143. doi: 10.3389/fphar.2025.1542143. eCollection 2025.
肝组织学评估非酒精性脂肪性肝病的可靠性和非酒精性脂肪性肝病活动评分的扩展。
Hepatology. 2022 Oct;76(4):1150-1163. doi: 10.1002/hep.32475. Epub 2022 Apr 6.
4
Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.气球样变肝细胞特征识别的复杂性：为非酒精性脂肪性肝病基于人工智能的成像定义一个训练图谱。
J Hepatol. 2022 May;76(5):1030-1041. doi: 10.1016/j.jhep.2022.01.011. Epub 2022 Jan 25.
5
Digital Pathology Enables Automated and Quantitative Assessment of Inflammatory Activity in Patients with Chronic Liver Disease.数字病理学可实现慢性肝病患者炎症活动的自动化和定量评估。
Biomolecules. 2021 Dec 2;11(12):1808. doi: 10.3390/biom11121808.
6
Non-Alcoholic Fatty Liver Disease: Implementing Complete Automated Diagnosis and Staging. A Systematic Review.非酒精性脂肪性肝病：实现完全自动化诊断与分期。一项系统评价。
Diagnostics (Basel). 2021 Jun 12;11(6):1078. doi: 10.3390/diagnostics11061078.
7
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease.KASL临床实践指南：非酒精性脂肪性肝病的管理
Clin Mol Hepatol. 2021 Jul;27(3):363-401. doi: 10.3350/cmh.2021.0178. Epub 2021 Jun 22.
8
Liver biopsy in the quantitative assessment of liver fibrosis in nonalcoholic fatty liver disease.肝活检在非酒精性脂肪性肝病肝纤维化定量评估中的应用。
Indian J Pathol Microbiol. 2021 Jun;64(Supplement):S104-S111. doi: 10.4103/IJPM.IJPM_947_20.
9
Recent advances in nonalcoholic fatty liver disease metabolomics.非酒精性脂肪性肝病代谢组学的最新进展。
Clin Mol Hepatol. 2021 Oct;27(4):553-559. doi: 10.3350/cmh.2021.0127. Epub 2021 Jun 8.
10
Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis.人工智能在非酒精性脂肪性肝病和纤维化预测中的应用。
J Gastroenterol Hepatol. 2021 Mar;36(3):543-550. doi: 10.1111/jgh.15385.